Announcement PDF ASX Announcement Invion Limited (ASX Code IVX) Section 708A Cleansing Statement 21 September 2022 This notice is given by Invion Limited (Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). The Company hereby confirms that: (a) on 16 September 2022, the Company issued 3,578,437 fully paid ordinary shares at an issue price of $0.00 per share (Ordinary Shares); (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act; (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act; (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has compiled with: (e) (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company and; (ii) section 674 of the Corporations Act as it applies to the Company; and as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act. This announcement is authorised for release by the Board of Directors of Invion Limited. Investor and Media enquiries: Thian Chew (Chairman) T: +61 3 8618 6843 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) T: +61 409 341 613 E: brendon@vantagepointpartners.com.au Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 3 9692 7222 W: www.inviongroup.com About Invion Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights to the PhotosoftTM technology for all cancer indications and Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). This announcement was approved for release by the Board of Directors. About Photodynamic Therapy (PDT) Invion is developing PhotosoftTM technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 3 9692 7222 W: www.inviongroup.com